Could early antibiotic stop be safe for kids with cancer?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female patients ≤18 years of age expected to develop prolonged neutropenia (\>7 days), with: * Acute myeloblastic leukaemia at any phase of chemotherapy * Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases * Biphenotypic leukaemia at any phase of chemotherapy * Lymphoblastic lymphoma in induction and consolidation phases * B-cell and anaplastic lymphoma receiving high-intensity chemotherapy * Solid tumours receiving high-intensity chemotherapy * Relapsed leukaemia at any phase of treatment 2. Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) \<500 neutrophils/mm³, or expected to fall below this value within the next 48-72 hours. 3. Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days/week for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study). 4. Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following: * CRP \<9 mg/dL * PCT \<0.5 ng/mL * Absence of hypotension 5. No microbiologically documented bacterial infection 48-72 hours after the FN episode. 6. Good clinical evolution 48-72 hours after the FN episode, defined as: * Afebrile for \>48 hours (axillary temperature \<38°C) * Haemodynamically stable * Stable paediatric early warning score (PEWS) 7. CRP \<5 mg/dL, or CRP \<9 mg/dL and PCT \<0.5 ng/mL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode). 8. ANC \<500 neutrophils/mm³ at the time of randomisation. 9. Signed informed consent from the patient and/or parent(s)/legal representative(s). 10. Patient and/or parent(s)/legal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study. 11. Patient and/or parent(s)/legal representative(s) must be considered reliable and capable of adhering to the protocol. Exclusion Criteria: 1. Antibiotic treatment at the time of the FN episode different from that used prophylactically. 2. Empirical antibiotic treatment different from that recommended in international guidelines. 3. Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death). 4. Active participation in the same study at the onset of the current FN episode. 5. Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results. 6. Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol. 7. Female patients who are pregnant or breastfeeding